Undisclosed PROTAC degrader / Arvinas, Bayer - LARVOL DELTA

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) - "Submit two investigational new drug (IND)/clinical trial authorization (CTA) applications for the Company’s BCL6 (oncology)...Progress at least two additional PROTAC protein degrader programs into IND- or CTA-enabling studies by year-end 2023....The increase in research and development expenses of $8.4 million for the quarter was primarily due to increases our AR program of $5.2 million, which includes ARV-766 and bavdegalutamide, and our ER program of $6.2 million, which is net of the cost sharing of vepdegestrant under the Vepdegestrant (ARV-471) Collaboration Agreement, offset by a decrease in our platform and exploratory programs of $3.0 million."

Commercial • IND • Oncology